


Curriculum Vitae

Name	BORA LIM	
Current Position & Affiliation	Associate Professor, Director of Translational Research Breast Oncology, Baylor College of Medicine. Dan L. Duncan Comprehensive Cancer Center Associate Director for Clinical Science, Lester and Sue Smith Breast Center	
Country	Singapore	

Educational Background

Degree-Granting Education

Ewha Womans University, School of Medicine, Seoul, Korea, Republic of, 3/1998-2/2004,

Degree: Doctor of Medicine (M.D.)

Postgraduate Training

Clinical Internship, Surgery, Catholic Medical Center, Seoul, Korea, Republic of, 3/2004-2/2005

Clinical Residency, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, 8/2007-6/2010

Chief Medical Residency, Internal Medicine, Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia, PA, 7/2010-6/2011

Clinical Fellowship, Hematology-Oncology, Penn State Hershey Medical Center, Penn State College of Medicine, Hershey, PA, 7/2011-6/2014

Research Fellowship, Experimental therapeutics, Penn State Hershey Cancer Institute, El-Deiry Laboratory of Experimental Therapeutics, Hershey, PA, 7/2012-6/2014

Professional Experience

Current Appointment:

Associate Professor, Director of Translational Research, Breast Research Program

Breast Oncology, Baylor College of Medicine. Dan L. Duncan Comprehensive Cancer Center

Associate Director for Clinical Science, Lester and Sue Smith Breast Center

Previous Appointment:

Assistant Professor, Breast Medical Oncology, Section of the Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Clinical Research Director, Morgan Welch IBC Research and Clinic Program, Division of Cancer Medicine, Morgan Welch Inflammatory Breast Cancer Research and Clinic Program, Houston, TX

Professional Organizations

National and International

American College of Physicians, Member, 09/2011-08/2040

American Society of Clinical Oncology, Member, 09/2011-08/2040

American Society of Hematology, Member, 09/2011-08/2040

American Association for Cancer Research, Member, 09/2012-08/2040

Korean Society of Medical Oncology, Republic of Korea (S Korea), Scientific Member, 4/2014-08/2040

South Western Oncology Group, Member, Translational research committee & Breast Working Group, 3/2015-08/2040

Metastasis Research Society, Member, 07/2017

Aspen Cancer Conference, CO, Member, 07/2017

TBCRC, Member, TNBC Working Group, 1/2021-present

Local/State

Pennsylvania Society of Oncology and Hematology, PA, Member, 7/2012-6/2014

Harris County Medical Society, Houston, TX, Member, 11/2014-08/2040

Texas Medical Association, TX, Member, 11/2014-08/2040

Main Scientific Publications

1. Full Papers in Peer Reviewed Journals

a. Published

1. **Lim B**, Cream LV, Harvey HA. Update on clinical trials: genetic targets in breast cancer. *Adv Exp Med Biol* 779:35-54, 2013. PMID: 23288634.
2. **Lim B**, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS. FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer. *Cancer Biol Ther* 14(8):711-9, 8/2013. e-Pub 6/2013. PMCID: PMC3841210.
3. Lee HJ, Park IA, Park SY, Seo AN, **Lim B**, Chai Y, Song IH, Kim NE, Kim JY, Yu JH, Ahn JH, Gong G. Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. *Breast Cancer Res Treat* 145(3):615-23, 6/2014. e-Pub 5/2014. PMID: 24820412.
4. Lee HJ, Song IH, Seo AN, **Lim B**, Kim JY, Lee JJ, Park IA, Shin J, Yu JH, Ahn JH, Gong G. Correlations Between Molecular Subtypes and Pathologic Response Patterns of Breast Cancers After Neoadjuvant Chemotherapy. *Ann Surg Oncol* 22(2):392-400, 2/2015. e-Pub 9/2014. PMID: 25192679.
5. Miller E, Lee HJ, Lulla A, Hernandez L, Gokare P, **Lim B**. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. *F1000Res* 3:198, 2014. e-Pub 8/2014. PMCID: PMC4224200.
6. Allen JE, Prabhu V, Talekar M, van den Heuvel AP, **Lim B**, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and pharmacological screens converge in identifying FLIP, BCL2 and IAP proteins as key regulators of sensitivity to the TRAIL-Inducing anticancer agent ONC201/TIC10. *Cancer Res* 75(8):1668-74, 4/2015. e-Pub 2/2015. PMCID: PMC4541796.
7. Le Du F, Eckhardt BL, **Lim B**, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? *Oncotarget* 6(15):12890-12908, 5/2015. e-Pub 5/2015. PMCID: PMC4536987.
8. **Lim B**, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. *Expert Opin Ther Targets* 25(9):1-15, 2015. e-Pub 5/2015. PMID: 26004811.
9. **Lim B**, Jiang Y. Current and Emerging Systemic Therapy in Gastro-Esophageal Cancer "The Old and New Therapy for Metastatic Disease, The Role of Adjuvant and Neoadjuvant Therapy for Localized Disease". *Curr Clin Pharmacol* 10(4):267-78, 2015. PMID: 26548904.

10. El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, **Lim B**, Yee NS, Harvey HA, Gatalica Z, Reddy S. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. *Cancer Biol Ther* 16(12):0, 2015. e-Pub 11/2015. PMID: PMC4847814.
11. Brennan M, **Lim B**. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer. *Adv Exp Med Biol* 867:327-37, 2015. PMID: 26530375.
12. Ma Y, Hao S, Wang S, Zhao Y, **Lim B**, Lei M, Spector DJ, El-Deiry WS, Zheng SY, Zhu J. A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. *Mol Cancer Ther* 14(3):835-43, 3/2015. e-Pub 1/2015. PMID: PMC4456279.
13. Matthew EM, Zhou L, Yang Z, Dicker DT, Holder SL, **Lim B**, Harouaka R, Zheng SY, Drabick JJ, Lamparella NE, Truica CI, El-Deiry WS. A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells. *Oncotarget* 7(4):3662-76, 1/2016. e-Pub 12/2015. PMID: PMC4826160.
14. Lee J, Galloway R, Grandjean G, Jacob J, Humphries J, Bartholomeusz C, Goodstal S, **Lim B**, Bartholomeusz G, Ueno NT, Rao A. Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. *J Cancer* 6(12):1306-19, 2015. e-Pub 10/2015. PMID: PMC4643087.
15. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, **Lim B**, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. *Oncotarget* 7(45):74380-74392, 11/2016. e-Pub 9/2016. PMID: PMC5342060.
16. **Lim B**, Hortobagyi GN. Current challenges of metastatic breast cancer. *Cancer Metastasis Rev* 35(4):495-514, 12/2016. e-Pub 12/2016. PMID: 27933405.
17. Matsuda N, **Lim B**, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. *Breast Cancer Res Treat*. e-Pub 2/2017. PMID: 28243898.
18. Kono M, Fujii T, **Lim B**, Karuturi MS, Tripathy D, Ueno N. Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. *JAMA Oncol*. e-Pub 3/2017. PMID: 28301631.

19. Matsuda N, **Lim B**, Wang X, Ueno NT. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. *Expert Opin Investig Drugs* 26(4):1-17, 4/2017. e-Pub 3/2017. PMID: 28271910.
20. Fouad TM, Barrera AM, Reuben JM, Lucci A, Woodward WA, Stauder MC, **Lim B**, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. *Lancet Oncol* 18(4):e228-e232, 4/2017. PMID: 28368261.
21. Ralff MD, Kline CLB Küçükkase OC, Wagner J, **Lim B**, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 demonstrates anti-tumor effects in both triple negative and non-triple negative breast cancers through TRAIL-dependent and TRAIL-independent mechanisms. *Molecular Cancer Therapeutics*, 4/2017.
22. Torres-Adorno AM, Lee J, Kogawa T, Ordentlich P, Tripathy D, **Lim B**, Ueno NT. Histone deacetylase inhibitor enhances the efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and inflammatory breast cancer. *Clin Cancer Res*, 2017.
23. Sato N, Wakabayashi M, Nakatsuji M, Shimoji N, Sakamoto S, Ishida A, Lee J, **Lim B**, Ueno NT, Ishihara H, Inui T. MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. *Biochem Biophys Res Commun.*, 5/2017. PMID: 28576487.
24. Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, **Lim B**, Mellas N, Ueno NT, Fouad T. Novel therapeutic strategies in the treatment of triple-negative breast cancer. *Ther Adv Med Oncol.* 7(493-511), 7/2017. PMID: 28717401.
25. Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, **Lim B**, Shen Y, Ueno NT. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. *Ann Oncol* 28(10):2420-2428, 10/2017. PMID: 28961844.
26. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, **Lim B**, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. *Breast Cancer Res Treat*, 8/2017. PMID: 28831670.
27. Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, **Lim B**, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. *PLoS One* 12(9):e0185231, 2017. e-Pub 9/2017. PMID: 285619732.

28. He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, **Lim B**, Gong Y. Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. *Am J Clin Pathol*. e-Pub 2/2018. PMID: 29425258.
29. Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, **Lim B**, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT. Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. *Oncotarget* 9(6):6872-6882, 1/2018. e-Pub 1/2018. PMID: PMC5805522.
30. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, **Lim B**, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. *Cancer*. e-Pub 3/2018. PMID: 29579338.
31. Le-Petross HT, **Lim B**,. Role of MR Imaging in Neoadjuvant Therapy Monitoring. *Magn Reson Imaging Clin N Am* 26(2):207-220, 5/2018. e-Pub 3/2018. PMID: 29622126.
32. **Lim B**, Woodward WA, Wang X, Reuben JM, Ueno NT. Inflammatory breast cancer biology: the tumour microenvironment is key. *Nat Rev Cancer*. e-Pub 4/2018. PMID: 29703913.
33. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, **Lim B**, Tripathy D, Litton JK, Ueno NT. Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. *Breast Cancer Res Treat*. e-Pub 6/2018. PMID: 29915946.
34. **Lim B**, Matsuda N, Wang X, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. *JAMA Oncol*. e-Pub 6/2018. PMID: 29879283.
35. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, **Lim B**,. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. *Surg Clin North Am* 98(4):787-800, 8/2018. e-Pub 5/2018. PMID: 30005774.

36. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, **Lim B**, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. *J Cancer* 9(8):1437-1447, 2018. e-Pub 4/2018. PMID: PMC5929089.
37. Murthy RK, Raghavendra AS, Hess KR, Fujii T, **Lim B**, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. *Clin Breast Cancer*. e-Pub 7/2018. PMID: 30077429.
38. Harano K, Wang Y, **Lim B**, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT. Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. *PLoS One* 13(10):e0204513, 2018. e-Pub 10/2018. PMID: PMC6193579.
39. Lee J, **Lim B**, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. *Breast Cancer Res Treat*. e-Pub 3/2019. PMID: 30826934.
40. Kang S, Kim EH, Hwang JE, Shin JH, Jeong YS, Yim SY, Joo EW, Eun YG, Lee DJ, Sohn BH, Lee SH, **Lim B**, Lee JS. Prognostic significance of high metabolic activity in breast cancer: PET signature in breast cancer. *Biochem Biophys Res Commun* 511(1):185-191, 3/2019. e-Pub 2/2019. PMID: 30777332.
41. **Lim B**, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarczyk R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. *Br J Cancer*. e-Pub 5/2019. PMID: 31097774.

42. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, **Lim B**, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. *Eur J Radiol* 114:167-174, 5/2019. e-Pub 3/2019. PMID: PMC6481318.
43. Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, **Lim B**, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA. Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. *Cancers (Basel)* 11(5), 5/2019. e-Pub 5/2019. PMID: 31137625.
44. **Lim B**, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. *Cancers (Basel)*, 7/2019. e-Pub 2019.
45. Ding Q, Chen H, **Lim B**, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. *Human Pathol.*, 7/2019.
46. Lee J, **Lim B**, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT. Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. *Breast Cancer Res Treat* 176(1):251, 7/2019. PMID: 30982934.
47. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, **Lim B**, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. *Cancer Med.*, 12/2019. PMID: 31849202.
48. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, **Lim B**, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. *Oncologist*. e-Pub 1/2020. PMID: 32003919.
49. Yennurajalingam S, Carmack C, Balachandran D, Eng C, **Lim B**, Delgado M, Guzman Gutierrez D, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. *BMJ Support Palliat Care*. e-Pub 1/2020. PMID: 31924662.

50. Milbury K, Weathers SP, Durrani S, Li Y, Whisenant M, Li J, **Lim B**, Weinberg JS, Kesler SR, Cohen L, Bruera E. Online Couple-Based Meditation Intervention for Patients With Primary or Metastatic Brain Tumors and Their Partners: Results of a Pilot Randomized Controlled Trial. *J Pain Symptom Manage*. e-Pub 2/2020. PMID: 32061834.
51. **Lim B**, Lin Y, Navin N. Advancing Cancer Research and Medicine with Single-Cell Genomics. *Cancer Cell* 37(4):456-470, 4/2020. PMID: 32289270.
52. Espinosa Fernandez JR, Eckhardt BL, Lee J, **Lim B**, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. *PLoS One* 15(4):e0231953, 2020. e-Pub 4/2020. PMCID: PMC7192374.
53. Winer A, Denlinger CS, Vijayvergia N, Cohen SJ, Astaturov I, Dotan E, Gallant JN, Wang EW, Kunkel M, **Lim B**, Harvey HA, Sivik J, Korzekwa K, Ruth K, White K, Cooper HS, Ross EA, Zhou L, El-Deiry WS. [First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer](#). *Clin Colorectal Cancer*. 2020 Aug 19;. doi: 10.1016/j.clcc.2020.08.003. [Epub ahead of print] PubMed PMID: 32972830.
54. Wang X, Semba T, Phi LTH, Chainitikun S, Iwase T, **Lim B**, Ueno NT. [Targeting Signaling Pathways in Inflammatory Breast Cancer](#). *Cancers (Basel)*. 2020 Sep 1;12(9). doi: 10.3390/cancers12092479. Review. PubMed PMID: 32883032; PubMed Central PMCID: PMC7563157.
55. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, **Lim B**, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. [A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer](#). *Invest New Drugs*. 2020 Sep 28;. doi: 10.1007/s10637-020-00995-2. [Epub ahead of print] PubMed PMID: 32984932.
56. Kida K, Hess KR, **Lim B**, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. [Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer](#). *Cancers (Basel)*. 2020 Oct 24;12(11). doi: 10.3390/cancers12113105. PubMed PMID: 33114311; PubMed Central PMCID: PMC7690918.

57. Li P, Lu M, Shi J, Gong Z, Hua L, Li Q, **Lim B**, Zhang XH, Chen X, Li S, Shultz LD, Ren G. [Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis.](#) Nat Immunol. 2020 Nov;21(11):1444-1455. doi: 10.1038/s41590-020-0783-5. Epub 2020 Sep 21. PubMed PMID: 32958928; PubMed Central PMCID: PMC7584447.
58. Postlewait LM, Teshome M, DeSnyder SM, **Lim B**, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. [Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?.](#) Ann Surg Oncol. 2020 Nov;27(12):4603-4612. doi: 10.1245/s10434-020-08891-y. Epub 2020 Jul 24. PubMed PMID: 32710271.
59. **Lim B**, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE Jr, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. [A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer.](#) Oncologist. 2020 Nov 3;. doi: 10.1002/onco.13581. [Epub ahead of print] PubMed PMID: 33140515.
60. Crespo J, Sun H, Wu J, Ding QQ, Tang G, Robinson MK, Chen H, Sahin AA, **Lim B**. [Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.](#) PLoS One. 2020;15(11):e0241775. doi: 10.1371/journal.pone.0241775. eCollection 2020. PubMed PMID: 33180796; PubMed Central PMCID: PMC7660495.
61. Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, **Lim B**, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. [The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.](#) Ann Surg Oncol. 2021 Jan 5;. doi: 10.1245/s10434-020-09392-8. [Epub ahead of print] PubMed PMID: 33403525.
62. **Lim B**. PD-L1 in Breast Cancer: The Road to the Perfect Biomarker is Fraught with Uncertainty. J Natl Cancer Inst. 2021 Feb 1:djab005. doi: 10.1093/jnci/djab005. [Online ahead of print] PMID: 33523229